224 related articles for article (PubMed ID: 22190492)
21. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.
Huang GC; Ouyang X; Epstein RJ
Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):113-9. PubMed ID: 9512468
[TBL] [Abstract][Full Text] [Related]
22. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF.
Saito T; Okada S; Ohshima K; Yamada E; Sato M; Uehara Y; Shimizu H; Pessin JE; Mori M
Endocrinology; 2004 Sep; 145(9):4232-43. PubMed ID: 15192046
[TBL] [Abstract][Full Text] [Related]
23. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
Hughes JB; Berger C; Rødland MS; Hasmann M; Stang E; Madshus IH
Mol Cancer Ther; 2009 Jul; 8(7):1885-92. PubMed ID: 19584234
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
25. Effect of lipid mimetics of GM3 and lyso-GM3 dimer on EGF receptor tyrosine kinase and EGF-induced signal transduction.
Haga Y; Hatanaka K; Hakomori SI
Biochim Biophys Acta; 2008 Mar; 1780(3):393-404. PubMed ID: 18036568
[TBL] [Abstract][Full Text] [Related]
26. Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study.
Motamedi Z; Rajabi-Maham H; Azimzadeh Irani M
J Mol Model; 2021 Nov; 27(12):361. PubMed ID: 34817689
[TBL] [Abstract][Full Text] [Related]
27. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes.
Wu CJ; Qian X; O'Rourke DM
DNA Cell Biol; 1999 Oct; 18(10):731-41. PubMed ID: 10541432
[TBL] [Abstract][Full Text] [Related]
28. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy.
Nagy P; Jenei A; Kirsch AK; Szöllosi J; Damjanovich S; Jovin TM
J Cell Sci; 1999 Jun; 112 ( Pt 11)():1733-41. PubMed ID: 10318765
[TBL] [Abstract][Full Text] [Related]
29. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
Alvarado D; Klein DE; Lemmon MA
Nature; 2009 Sep; 461(7261):287-91. PubMed ID: 19718021
[TBL] [Abstract][Full Text] [Related]
30. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling.
Wong L; Deb TB; Thompson SA; Wells A; Johnson GR
J Biol Chem; 1999 Mar; 274(13):8900-9. PubMed ID: 10085134
[TBL] [Abstract][Full Text] [Related]
31. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866
[TBL] [Abstract][Full Text] [Related]
32. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.
Wang Z; Zhang L; Yeung TK; Chen X
Mol Biol Cell; 1999 May; 10(5):1621-36. PubMed ID: 10233167
[TBL] [Abstract][Full Text] [Related]
33. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
[TBL] [Abstract][Full Text] [Related]
35. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Zhang Q; Park E; Kani K; Landgraf R
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13237-42. PubMed ID: 22733765
[TBL] [Abstract][Full Text] [Related]
36. EGF activates ErbB-2 and stimulates phosphatidylinositol 3-kinase in human airway smooth muscle cells.
Krymskaya VP; Hoffman R; Eszterhas A; Kane S; Ciocca V; Panettieri RA
Am J Physiol; 1999 Feb; 276(2):L246-55. PubMed ID: 9950886
[TBL] [Abstract][Full Text] [Related]
37. Intensification of growth factor receptor signalling by phorbol treatment of ligand-primed cells implies a dimer-stabilizing effect of protein kinase C-dependent juxtamembrane domain phosphorylation.
Gulliford T; Ouyang X; Epstein RJ
Cell Signal; 1999 Apr; 11(4):245-52. PubMed ID: 10372802
[TBL] [Abstract][Full Text] [Related]
38. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
39. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
40. Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence.
He L; Hristova K
Sci Rep; 2012; 2():854. PubMed ID: 23152945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
